Ampio Pharmaceuticals: Overbought and Under-Capitalized
Most Popular - Shares of Ampio Pharmaceuticals (AMPE) were on a tear in the past four weeks, climbing from $3.39 at the end of December to a recent … Continue Reading
Read nowAuthor Archives: Jake King
Game-Changing Zerenex Results, More Than 1 Year In Cash; KERX To Trade Higher
Long Ideas - Keryx BioPharmaceuticals (NASDAQ:KERX) has been a booming success for PropThink, with the stock doubling since PropThink first got behind the Zerenex data in mid-October. And, our … Continue Reading
Read nowTTHI To Trade Higher Into Upcoming Trial Results For Diabetes Drug
Long Ideas - Transition Therapeutics (TTHI) is mostly known for its Alzheimer’s disease (AD) treatment candidate, ELND005, however partner Elan Corp. (ELN) is currently focused on advancing the … Continue Reading
Read nowBaxter’s Earnings Call Reveals Good News For HALO
Long Ideas - Baxter International (BAX) reported financial results for the fourth quarter and full-year 2012, and in a conference call following the press release, expressed confidence that … Continue Reading
Read nowNEJM Articles Affirm Comparability of AFFY’s Omontys To Epogen
Long Ideas - The results of 4 head-to-head trials comparing the safety and efficacy of Affymax’s (AFFY) Omontys (pegesanitide) and. Amgen’s leading erythropoietin stimulating agents (ESAs), Epogen and … Continue Reading
Read now4Q and 2013 Guidance Confirm Ofirmev Growth, Potential for CADX
Long Ideas - Cadence Pharmaceuticals (CADX) released full year 2013 guidance for Ofirmev sales of between $94M and $100M and increased revenue estimates in 4Q12 to approximately $17M, … Continue Reading
Read nowZerenex Phase III Data Imminent; Still High Odds for KERX To Succeed With This Drug
Long Ideas - Keryx BioPharmaceuticals (NASDAQ:KERX) miscalculated the timing for when its CRO (contract research organization) would deliver Phase III results for Zerenex, the company’s phosphate-binder candidate for … Continue Reading
Read now